Do You Lose More Weight on Wegovy or Zepbound? A Comprehensive Comparison

Last reviewed: June 25, 2026

Last updated: June 25, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Two FDA-approved injectable medications now dominate the weight loss market: Wegovy (semaglutide) and Zepbound (tirzepatide). Both work through GLP-1 receptor activation, yet they deliver measurably different outcomes in clinical practice. Understanding their mechanisms, trial results, and individual factors helps patients make informed choices about which approach may align with their health goals.

Clinical Trial Results: Zepbound and Wegovy Head-to-Head

The SUSTAIN and STEP trials established baseline expectations for semaglutide weight loss, with patients losing an average of 15-18% of body weight over 68 weeks at maximum doses. Tirzepatide trials, including SURMOUNT and SURPASS, demonstrated average reductions of 21-22% of body weight at the highest tested doses over similar timeframes. These numerical differences reflect tirzepatide's dual action on both GLP-1 and GIP receptors, whereas semaglutide targets the GLP-1 pathway exclusively.

Raw percentages tell only part of the story. A 200-pound person losing 18% weighs 164 pounds; the same person losing 22% weighs 156 pounds—an eight-pound difference. For some patients, that margin proves clinically meaningful; for others, either outcome achieves their target weight and health improvements. Trial populations also differed slightly in baseline characteristics, medication dosing schedules, and follow-up duration, which influences direct comparison validity.

How Semaglutide and Tirzepatide Work Differently in Your Body

Semaglutide (Wegovy) activates GLP-1 receptors in the brain, pancreas, and gut, triggering appetite suppression, improved blood sugar control, and delayed stomach emptying. Tirzepatide (Zepbound) activates both GLP-1 and GIP receptors simultaneously, engaging additional metabolic pathways. The GIP receptor modulates glucose-dependent insulin secretion and may enhance the satiety signal more potently than GLP-1 activation alone.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

How Your Genetics Relate to GLP-1 Pathways

Genetic predisposition matters more than medication choice alone. Patients carrying certain variants in GIPR genes show enhanced receptor responsiveness, meaning tirzepatide's dual activation produces markedly better results in these individuals. Conversely, those with specific FTO polymorphisms may benefit from aggressive appetite suppression that either medication provides, but the magnitude of response depends on baseline appetite-drive genetics rather than the drug itself.

Lifestyle factors compound medication efficacy. Consistent physical activity, protein-rich nutrition, and adequate sleep amplify weight loss from either semaglutide or tirzepatide. Patients who maintain sedentary habits or high-calorie diets despite medication typically lose less weight, regardless of whether they choose Wegovy or Zepbound. Metabolic health status at baseline—including insulin resistance, inflammation markers, and liver function—also influences both the speed and total magnitude of weight reduction achievable.

Cost, Access, and Personalization With PlexusDx Compounded Options

Brand-name Wegovy and Zepbound carry list prices exceeding $900–$1,300 monthly, often with insurance coverage gaps or prior authorization delays. PlexusDx compounded tirzepatide injection is $289/mo month-to-month (or $249/mo on the 6-month plan) through licensed 503A compounding pharmacies, eliminating flat per-compound pricing surprises. Your dose may need to go up. Your price won't. PlexusDx also offers compounded semaglutide injection at $189/mo month-to-month, or from $149/mo on the 6-month plan, providing both medication options at transparent, accessible rates across all 50 states without membership fees or insurance requirements.

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Side Effects and Tolerability: Semaglutide vs. Tirzepatide

Nausea, constipation, and reduced appetite represent the most common side effects of both medications, occurring because both activate GLP-1 receptors throughout the gastrointestinal tract. Tirzepatide's dual-receptor action sometimes triggers slightly higher rates of nausea in early dose escalation phases, though most patients adapt within one to two weeks. Semaglutide tolerability tends to feel more predictable for patients familiar with single-pathway GLP-1 agonists, as the pharmacology remains simpler.

Rare but serious side effects include thyroid concerns (both drugs carry boxed warnings for personal or family history of medullary thyroid carcinoma) and gallbladder complications from rapid weight loss. Neither medication is appropriate for patients with active pancreatitis or severe renal impairment. Side effect severity and duration vary widely between individuals based on genetics, gut microbiome composition, and concurrent medications. Starting with PlexusDx's Microdose GLP-1 Protocol at $129 per month allows cautious dose titration, minimizing side effect intensity while establishing tolerability before advancing to standard-dose tirzepatide or semaglutide.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Does Zepbound always produce more weight loss than Wegovy?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Which medication works faster, semaglutide or tirzepatide?

Both require dose escalation over 16-20 weeks to reach therapeutic levels, so neither produces rapid results. Tirzepatide typically shows measurable weight loss within 2-4 weeks at therapeutic doses due to its stronger appetite-suppression effect, while semaglutide's onset often requires 3-6 weeks. However, the rate of dose escalation, adherence to injections, and concurrent lifestyle changes influence speed more than the medication choice itself.

Can I switch from Wegovy to Zepbound if I'm not satisfied with results?

Yes. After 12-16 weeks at maximum semaglutide dose, if weight loss plateaus below your goal, switching to tirzepatide is clinically reasonable under medical supervision. PlexusDx compounded tirzepatide injection is $289/mo month-to-month (or $249/mo on the 6-month plan), allowing seamless transition without your dose may need to go up - your price won't adjusts. A washout period of one week between stopping semaglutide and starting tirzepatide minimizes overlap and reduces nausea risk.

Are compounded semaglutide and tirzepatide as safe as brand-name versions?

Yes. PlexusDx sources all compounded medications from licensed 503A compounding pharmacies that follow strict FDA regulations, quality controls, and sterility standards matching pharmaceutical manufacturers. Compounded semaglutide and tirzepatide contain identical active ingredients to Wegovy and Zepbound; the difference is manufacturing site and cost. Both are equally effective and safe when prescribed and monitored appropriately by qualified healthcare providers.

How does genetic testing help me choose between these medications?

PlexusDx's Precision Peptide Genetic Test ($298) analyzes your GIPR, FTO, and MC4R variants across 14 metabolic pathways. Patients with high-sensitivity GIPR variants typically respond more dramatically to tirzepatide's dual activation, while those with certain FTO polymorphisms may respond equally well to either medication's appetite-suppression effect. This genetic roadmap helps your provider select and dose the medication predicted to deliver your best outcome.

Related Reading

• Wegovy Vs Zepbound Weight Loss
• Can My Dna Tell Me How Do You Lose Weight
• Can A Dna Test Tell Me How Do You Lose Weight
• Can You Get A Dna Test To See How Do You Lose Weight

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.